A Phase IIa Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Multiple Doses of Inhaled RNS60 and Budesonide on the Late Phase Asthmatic Response to Allergen Challenge in Patients With Mild Asthma.

Trial Profile

A Phase IIa Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Multiple Doses of Inhaled RNS60 and Budesonide on the Late Phase Asthmatic Response to Allergen Challenge in Patients With Mild Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs RNS 60 (Primary) ; Budesonide
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Revalesio
  • Most Recent Events

    • 04 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2015 According to ClinicalTrials.gov record, this trial has been amended to no longer be a cross-over trial; it will be parallel (RNS60/placebo) 1 period study and no longer involves the administration of budesonide.
    • 07 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top